Skip to main content

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

NEW YORK – Thermo Fisher Scientific said on Monday that it has received Emergency Use Authorization from the US Food and Drug Administration for its Amplitude Solution with the TaqPath COVID-19 High-Throughput Combo Kit.

This modular system uses a high-throughput version of the Applied Biosystems TaqPath COVID-19 Combo Kit, which received an EUA in March 2020, enabling laboratories to rapidly scale their capacity for high-sensitivity PCR testing. The Amplitude Solution is a molecular diagnostic testing system that combines Thermo Fisher's extraction and real-time PCR instruments with liquid handling products from Tecan Group, the company said, adding that the kit's multi-gene target design and updated interpretive software may help labs detect SARS-CoV-2 variants. The firm also noted that the Amplitude Solution will allow labs to process up to 8,000 samples per day, with minimal staffing resources and a secured supply of kits, reagents, and consumables, and that the system has already been implemented in labs in Europe and Japan.

"For population-wide testing programs, lab-based PCR is the best fitting technology, providing confidence in results, capacity to process thousands of samples a day, and consistent, reliable turnaround times," Thermo Fisher Chief Operating Officer Mark Stevenson said in a statement. "The Amplitude Solution can help support a systematic testing strategy by enabling labs to quickly scale their testing and begin processing high-volume samples, even with limited personnel."

Thermo Fisher has received EUAs and CE marks for multiple COVID diagnostics. In addition to the EUA it received for the TaqPath COVID-19 Combo Kit in March 2020, the company received the CE mark for the high-throughput version of test kit this February, and also received an EUA for a multiplex real-time PCR test for COVID-19 and influenza in the same month. Including this latest test kit, the company has six diagnostics aimed at COVID-19 or a combination of infectious diseases approved for use in the US and Europe.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.